This interaction specifically, blocks the binding between IGF2BP1 and its target RNAs, such as Kirsten rat sarcoma viral oncogene homologue (Kras), ultimately suppressing tumorigenic properties of tumor cells. The gene discussed is IGF2BP1; the disease is neoplasm.